Skip to main content
Premium Trial:

Request an Annual Quote

Jim Manzi, Steve Lundy

Premium
Thermo Fisher Scientific this week named Jim Manzi non-executive chairman of its board. He succeeds Paul Meister, who retired as chairman on April 10. Manzi was chairman of Thermo Electron from December 2003 through Nov. 9, 2006, when Thermo completed its merger with Fisher Scientific. He is currently chairman of Stonegate Capital. He was president, chairman, and CEO of Lotus Development from 1984 to 1995, when it was acquired by IBM.
 

 
Ciphergen this week appointed Steve Lundy senior vice president of sales and marketing, effective May 16. Lundy comes from GeneOhm, a division of BD Diagnostics, where he had been vice president of sales and marketing since 2003. He also has held various marketing positions at Esoterix and Bayer Diagnostics.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.